Strides Pharma Science Friday Said Its Step-Down Wholly-Owned Subsidiary Has Received Approval From The Us Health Regulator For Solifenacin Succinate Tablets, Used To Treat Overactive Bladder.The Approved Product Is A Generic Version Of Vesicare Tablets Of Astellas Pharma Us, Inc.Strides Pharma Global, Singapore, Has Received Approval For Solifenacin Succinate Tablets, 5 Mg And 10 Mg, From The United States Food And Drug Administration (Usfda), Strides Pharma Science Said In A Regulatory Filing.Citing Iqvia Data, The Company Said The Us Market For Solifenacin Succinate Tablets, 5 Mg And 10 Mg Is Approximately Usd 820 Million.Strides Said The Product Will Be Manufactured At Alathur Facility In Chennai And Will Be Marketed By Strides Pharma In The Us Market.
